Data from A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer

Autor: Fernando Ulloa-Montoya, Jamila Louahed, Vincent G. Brichard, Bart Spiessens, Channa Debruyne, Patrick Therasse, Fawn Wang, Susana Salceda, Hans van Houwelingen, Jelle Goeman, Djordje Atanackovic, Lecia V. Sequist, Johan F. Vansteenkiste, John M. Kirkwood, Helen J. Gogas, Peter Hersey, Brigitte Dreno, Muriel Debois, Andrea Callegaro, Benjamin Dizier

Purpose:Immune components of the tumor microenvironment (TME) have been associated with disease outcome. We prospectively evaluated the association of an immune-related gene signature (GS) with clinical outcome in melanoma and non–small cell lung c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ba2c738c013635e68f3f047ad124642
https://doi.org/10.1158/1078-0432.c.6528486

A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S/AS01

Autor: James E, Moon, Melissa E, Greenleaf, Jason A, Regules, Muriel, Debois, Elizabeth H, Duncan, Martha, Sedegah, Ilin, Chuang, Cynthia K, Lee, April K, Sikaffy, Lindsey S, Garver, Karen, Ivinson, Evelina, Angov, Danielle, Morelle, Marc, Lievens, Christian F, Ockenhouse, Viseth, Ngauy, Opokua, Ofori-Anyinam

Publikováno v: Vaccine. 39(43)

We previously demonstrated that RTS,S/AS0149 participants (P-Fx: 25; NP-Fx: 24) received a fractional (1/5th dose-volume) RTS,S/AS01Overall vaccine efficacy against re-challenge was 53% (95% CI: 37-65%), and similar for P-Fx (52% [95% CI: 28-68%]) an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::08a1214d8923673f1b6898ad646b9bc8
https://pubmed.ncbi.nlm.nih.gov/34593270

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

Autor: Benjamin Dizier, Andrea Callegaro, Robert M. Conry, Jean-Jacques Grob, Vincent Brichard, Laurent Machet, John F. Thompson, Evgeny Levchenko, Kamil Drucis, Mario Santinami, Gabriela Cinat, Sergii Korovin, John M. Kirkwood, Jaroslaw Jaroszek, Wim H. J. Kruit, Brigitte Dréno, Hans C. van Houwelingen, Bernard Guillot, Axel Hauschild, Jelle J. Goeman, Thomas Jouary, Peter Hersey, Ralf Gutzmer, Susana Puig, P. Therasse, Bernard Mark Smithers, Florent Grange, Bart Spiessens, Channa Debruyne, Piotr Rutkowski, Lev V. Demidov, Alessandro Testori, Igor Bondarenko, Muriel Debois, Fernando Ulloa-Montoya, Jamila Louahed, Ivana Krajsová, John A. Thompson

Publikováno v: The Lancet Oncology
The Lancet Oncology, 19(7), 916-929
Lancet Oncology
Lancet Oncology, Elsevier, 2018, 19 (7), pp.916--929. ⟨10.1016/S1470-2045(18)30254-7⟩
Lancet Oncology, 19(7), 916-929. Lancet Publishing Group

International audience; BACKGROUND: Despite newly approved treatments, metastatic melanoma remains a life-threatening condition. We aimed to evaluate the efficacy of the MAGE-A3 immunotherapeutic in patients with stage IIIB or IIIC melanoma in the ad

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3122602f081ca83557b035172ba56d69
https://doi.org/10.1016/s1470-2045(18)30254-7

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

Autor: Tonu Vanakesa, Oleg Gladkov, Katalin Udud, Patrick Therasse, Byoung Chul Cho, Jean-Louis Pujol, Moon Soo Kim, Libor Havel, Johan Vansteenkiste, Hans Hoffman, Nasser K. Altorki, Haruhiko Kondo, Paul D. Taylor, Jacek Jassem, Marcin Zieliński, Mei Lin Liao, Jamila Louahed, Tetsuya Mitsudomi, Tommaso De Pas, Konstantinos Zarogoulidis, Anders Bugge, Jubrail Dahabreh, Vincent Brichard, Muriel Debois, Haruhiku Nakayama, Jianxing He, Hirohito Tada, Masahiro Yoshimura, Emilio Esteban Gonzalez, C. Debruyne

Publikováno v: The Lancet Oncology. 17:822-835

Summary Background Fewer than half of the patients with completely resected non-small-cell lung cancer (NSCLC) are cured. Since the introduction of adjuvant chemotherapy in 2004, no substantial progress has been made in adjuvant treatment. We aimed t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cfba095f4c0d44aa7a2da0e05af827f
https://doi.org/10.1016/s1470-2045(16)00099-1

Adjusted significance levels for subgroup analyses in clinical trials

Autor: Bart Spiessens, Muriel Debois

Publikováno v: Contemporary Clinical Trials. 31:647-656

Subgroup analyses in clinical trials are becoming increasingly important. In cancer research more and more targeted therapies are explored and probably only a portion of the whole population will benefit from them. Subgroups of interest can be analyz

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a01f95a99a0bbcf792ca38f3134fa137
https://doi.org/10.1016/j.cct.2010.08.011